BioVaxys Technology Corp. Updates on Management Cease Trade Order Status

BioVaxys Technology ( (TSE:BIOV) ) has provided an announcement.

BioVaxys Technology Corp. has announced a bi-weekly update regarding a management cease trade order (MCTO) due to delays in filing its audited annual financial statements. The company is working with its auditor to complete the filings by March 30, 2025, and assures that while the MCTO is in effect, public trading of its shares will continue, although trading by its CEO and CFO is restricted. This situation highlights the company’s commitment to resolving the issue while maintaining transparency with stakeholders.

More about BioVaxys Technology

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company based in British Columbia, Canada, focused on developing novel immunotherapies using its DPX™ immune-educating technology platform and HapTenix© ‘neoantigen’ tumor cell construct platform. The company’s pipeline includes treatments for cancers, infectious diseases, and other immunological fields, with products like maveropepimut-S in Phase II development and BVX-0918 entering Phase I.

YTD Price Performance: -24.00%

Average Trading Volume: 385,681

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $8.95M

For an in-depth examination of BIOV stock, go to TipRanks’ Stock Analysis page.